Maraviroc nonresponders show increased peripheral T-cell activation and naive T-cell skewing. (A) CD38 expression by MFI on CD4⁺ T cells at day 30 from maraviroc-treated patients who developed or did not develop grade 2-4 GVHD by day 100. (B) Percentage of CD38⁺ cells among CD4⁺ T cells at day 30 from maraviroc-treated patients who developed or did not develop grade 2-4 GVHD by day 100. (C) Day 30 percentage of naive CD4⁺ T cells from patients who developed or did not develop grade 2-4 GVHD by day 100. (D) Percentage of naive (N), central memory (CM), effector memory (EM), and effector memory RA (EMRA) among CD4⁺ T cells at day 30. (E) Day 30 percentage of CD8⁺ T cells from patients who developed or did not develop grade 2-4 GVHD by day 100. (F) Percentage of indicated T-cell subsets among CD8⁺ T cells at day 30. *P < .05, Student t test.